国浩律师（上海）事务所 法律意见书 本法律意见书中不存在虚假、严重误导性陈述及重大遗漏，否则本所律师愿 意承担相应的法律责任。 本所律师仅依据本法律意见书出具日以前发生的事实及本所律师对该事实 的了解，并仅就本次股东大会召开程序所涉及的中国相关法律问题发表法律意 见。 本所律师同意将本法律意见书作为公司 2025 年第三次临时股东大会的必备 文件公告，并依法对本所出具的法律意见承担责任。 本所律师已经对与出具法律意见书有关的所有文件材料进行审查判断，并据 此出具法律意见如下： 国浩律师（上海）事务所 关于杭华油墨股份有限公司 2025 年第三次临时股东大会的法律意见书 致：杭华油墨股份有限公司 杭华油墨股份有限公司（以下简称"公司"）2025 年第三次临时股东大会定 于 2025 年 10 月 20 日召开，国浩律师（上海）事务所（以下简称"本所"）接受 公司的委托，指派陈晓纯律师、毛一帆律师（以下简称"本所律师"）对本次股东 大会进行见证，并依据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》（以下简称"《证券法》"）、中国证券监督管理委员会发布 的《上市公司股东会规则》及其他 ...

Group 1 - The core viewpoint of the article highlights the strong performance of rare earth permanent magnet stocks in the A-share market, driven by supply control and favorable policies in the rare earth industry [1] - Citigroup's report indicates that the rare earth industry is in the early to mid-stage of an upward cycle, benefiting from China's supply management and its strategic position in energy transition, despite uneven downstream demand [1] - The price of rare earth concentrate has increased by 37% to 26,205 yuan/ton (excluding tax) for Q4 2025, marking the highest level since Q2 2023 [1] Group 2 - Notable stock performances include Xinlaifu with a 20% increase, Baogang Co. and Antai Technology both reaching 10% limits, and China Rare Earth approaching a limit increase [2] - The total market capitalization of Baogang Co. is 139 billion yuan, with a year-to-date increase of 65.05% [2] - North Rare Earth has a market capitalization of 222.3 billion yuan, with a remarkable year-to-date increase of 190.13% [2]

杭华油墨股份有限公司 2025 年第三次临时股东大会 股票代码：688571 股票简称：杭华股份 杭华油墨股份有限公司 2025 年第三次临时股东大会 会议资料 召开时间 2025 年 10 月 杭华油墨股份有限公司 2025 年第三次临时股东大会 杭华油墨股份有限公司 2025 年第三次临时股东大会会议资料 目 录 | 2025 年第三次临时股东大会须知 1 | | --- | | 2025 年第三次临时股东大会议程 3 | | 议案一：关于取消监事会、变更注册资本并修订《公司章程》等治理制度的议 | | 案 5 | | 议案二：关于续聘 2025 年度会计师事务所的议案 7 | 杭华油墨股份有限公司 2025 年第三次临时股东大会 杭华油墨股份有限公司 2025年第三次临时股东大会须知 为了维护全体股东的合法权益，确保杭华油墨股份有限公司（以下简称"公 司"或"杭华股份"）股东大会的正常秩序和议事效率，保证大会的顺利进行，根 据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司股东大会规则》 以及《杭华油墨股份有限公司章程》（以下简称"《公司章程》"）等相关规定，特 制定本须知。 一、公司负责本次 ...

Core Viewpoint - Hanghua Co., Ltd. announced a change in the business scope of its subsidiary, Hangzhou Yunyizhen Color Technology Co., Ltd. (referred to as "Yunyizhen Color"), due to actual operational and business development needs [1] Group 1 - The subsidiary Yunyizhen Color has completed the registration procedures for the change of business scope [1] - The company has obtained a new business license issued by the Market Supervision Administration of Hangzhou's Gongshu District [1]

杭华油墨股份有限公司（以下简称"公司"或"杭华股份"）控股子公司杭 州云易臻彩科技有限公司（以下简称"云易臻彩"）因实际经营及业务发展需要， 对其经营范围进行了变更。近日，公司控股子公司云易臻彩已完成工商变更登记 手续并取得杭州市拱墅区市场监督管理局换发的《营业执照》，变更后的工商登 记具体信息如下： 证券代码：688571 证券简称：杭华股份 公告编号：2025-050 杭华油墨股份有限公司 关于控股子公司完成工商变更登记 并换发营业执照的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 住 所：浙江省杭州市拱墅区祥茂路 2 号 3 幢 301 室 特此公告。 杭华油墨股份有限公司董事会 2025 年 9 月 30 日 统一社会信用代码：91330105MABP0Q8M1P 名 称：杭州云易臻彩科技有限公司 类 型：其他有限责任公司 法定代表人：沈剑彬 经营范围：一般项目：技术服务、技术开发、技术咨询、技术交流、技术转 让、技术推广；工业互联网数据服务；软件销售；软件开发；油墨销售（不含危 险化学品）；计算机软硬件及 ...

Group 1 - Dongxing Medical plans to acquire 90% equity of Wuhan Yijiaobao for cash, which is expected to constitute a major asset restructuring [1] - Fosun Pharma's subsidiary plans to transfer 100% equity of Shanghai Cloning, with a transaction value of up to 1.256 billion yuan [1] Group 2 - *ST Songfa's subsidiary signed a shipbuilding contract worth approximately 400-600 million USD for four VLCCs, expected delivery between late 2026 and mid-2027 [3] - Qibin Group obtained financing support of up to 90 million yuan for share repurchase [4] Group 3 - Shapuaisi's shareholder plans to reduce holdings by up to 3% of the company's total shares [5] - *ST Kaixin intends to use up to 310 million yuan for cash management in safe and liquid financial products [6] Group 4 - Junchen Technology's shareholders plan to transfer 2.5% of the company's shares due to personal funding needs [7] - Jingliang Holdings received an administrative regulatory measure from Hainan Securities Regulatory Bureau for improper revenue recognition involving 299 million yuan [7] Group 5 - Tongcheng Holdings received a cash dividend of 24.6643 million yuan from Changsha Bank [9] - Shenyang Chemical appointed Chen Liguo as the new general manager [10] Group 6 - Huaguang Huaneng signed a contract for a 160 million yuan waste heat boiler project [15] - Shuxian Valley's subsidiary completed the re-registration of a health food product [16] Group 7 - Xuanta Pharmaceutical's new specification for a diabetes treatment drug was approved [17] - Panlong Pharmaceutical's application for a pain relief gel patch was accepted by the drug regulatory authority [18] Group 8 - Zhiguang Electric's subsidiary won a procurement contract worth 164 million yuan for a storage system [19] - Chitianhua's production facility resumed operations after maintenance [20] Group 9 - Haitong Development's application for a specific A-share issuance was accepted by the Shanghai Stock Exchange, aiming to raise 210 million yuan [20] - Risheng Technology's shareholders plan to transfer 4.02% of the company's shares [33] Group 10 - Pingmei Shares' controlling shareholder plans a strategic restructuring with Henan Energy Group [35] - Shenghui Integration's controlling shareholder committed not to reduce shareholdings for 12 months [37] Group 11 - Agricultural Bank and Bank of China will no longer establish supervisory boards, with their functions transferred to the audit committees [39][40] - Dongfang Yuhong's subsidiary signed a contract for a seawater pipeline project worth 2.524 billion USD [40][41] Group 12 - Ganfeng Lithium plans to introduce investors for a capital increase of up to 2.5 billion yuan [50] - Hanyu Pharmaceutical intends to raise up to 968 million yuan for various projects [51]

Group 1: Investment and Fundraising - Hanyu Pharmaceutical plans to raise no more than 968 million yuan for the development of semaglutide and other projects [1] - Ganfeng Lithium intends to introduce investors for a capital increase of up to 2.5 billion yuan [9] Group 2: Strategic Restructuring - Pingmei Shenma Holdings is undergoing a strategic restructuring as directed by the Henan provincial government, which will not affect the company's operations significantly [2][8] - Shennong Holdings is also involved in a strategic restructuring with no change in control or significant impact on operations [7][8] Group 3: Clinical Trials and Approvals - XinNuoWei's subsidiary received approval for clinical trials of a drug for treating mild Alzheimer's disease, marking a significant milestone in the development of biosimilar drugs [3] - Tainkang's subsidiary has received approval for clinical trials of CKBA cream for rosacea, a first-class innovative drug in China [4] - Baili Tianheng's drug, iza-bren, has been included in the list of breakthrough therapies, indicating its potential in treating advanced urinary tract cancer [5] Group 4: Contracts and Projects - Zhongyou Engineering signed an EPC contract worth 2.524 billion USD for a seawater pipeline project in Iraq, expected to positively impact future revenues [6]

Core Viewpoint - On September 25, no A-share listed companies disclosed any increase in shareholding, while 16 companies announced share reductions, indicating a trend of shareholder divestment in the market [1]. Summary by Category Share Reduction Details - Hanghua Co. plans to reduce up to 4.24 million shares of repurchased stock to supplement working capital [2] - Weili Sealing's shareholders plan to reduce up to 1% of the company's shares [2] - Milkewei's actual controller and shareholders intend to collectively reduce up to 4.02% of the company's shares [2] - Zhichun Technology's controlling shareholder reduced 4.2678 million shares on September 25 [2] - Xinao Micro's senior management plans to reduce up to 0.0134% of the company's shares [2] - Quanfeng Technology's Hesheng Health Insurance reduced 57.1419 million shares from September 22 to September 24 [2] - Morning Light Biological's senior management Li Fengfei plans to reduce up to 140,000 shares [2] - Everbright Jiabao's Jiading Jianye and Jiading Keti plan to reduce up to 1% of their shares [2] - Shengshi Technology's employee stock ownership platform plans to reduce up to 3% of the company's shares [2] - Xingsen Technology's actual controller Qiu Xingya reduced a total of 9.9639 million shares from August 5 to September 22 [2] - Haizheng Materials' Sinopec Capital plans to reduce up to 2.0267 million shares, accounting for 1% of the total share capital [2] - Zhengzhong Design's controlling shareholder plans to reduce up to 3% of the company's shares [2] - Baiya Co.'s three shareholders plan to collectively reduce up to 2% of the company's shares [2] - Jialiqi's shareholders plan to collectively reduce up to 3% of the company's shares [2] - Defu Technology's shareholders plan to collectively reduce up to 0.13% of the company's shares [2] - Jinyinhe's shareholders plan to reduce up to 0.35% of the company's total share capital [2] Market Signal - The MACD golden cross signal has formed, indicating a positive trend for certain stocks [1]

（编辑 任世碧） 证券日报网讯 9月25日晚间，杭华股份发布公告称，公司于2025年9月25日召开第四届董事会第十四次 会议，审议通过《关于回购股份集中竞价减持计划的议案》。根据公司于2024年2月8日在上海证券交易 所网站披露《杭华油墨股份有限公司关于以集中竞价交易方式回购公司股份的回购报告书》的有关要 求，为补充公司日常经营所需要的流动资金，公司计划自本公告披露之日起15个交易日后的3个月内， 通过集中竞价交易方式，按照市场价格累计减持不超过4，241，707股已回购股份，占公司总股本的 1%。 ...

Group 1 - The company, Hanghua Co., Ltd. (688571), announced on September 25 that it plans to reduce its holdings of repurchased shares by up to 4.2417 million shares, which represents 1% of the total share capital [1] - The reduction will occur through centralized bidding transactions within three months after 15 trading days [1] - The funds raised from this share reduction will be used to supplement the company's working capital for daily operations [1]